CHICAGO (Reuters) - Just as 23andMe has made peace with the US Food and Drug Administration, another direct-to-consumer genetics company is testing the regulatory waters with the launch of a $249 DNA test designed to predict drug response.br clear='all'/img width='1' height='1' src='http://reuters.us.feedsportal.com/c/35217/f/654220/s/4b4c9ced/sc/14/mf.gif' border='0'/div class="feedflare"
a href="http://feeds.feedburner.com/~ff/reuters/scienceNews?a=oB_NX2vmBaM:1oYfduIDgYM:yIl2AUoC8zA"img src="http://feeds.feedburner.com/~ff/reuters/scienceNews?d=yIl2AUoC8zA" border="0"/img/a a href="http://feeds.feedburner.com/~ff/reuters/scienceNews?a=oB_NX2vmBaM:1oYfduIDgYM:F7zBnMyn0Lo"img src="http://feeds.feedburner.com/~ff/reuters/scienceNews?i=oB_NX2vmBaM:1oYfduIDgYM:F7zBnMyn0Lo" border="0"/img/a a href="http://feeds.feedburner.com/~ff/reuters/scienceNews?a=oB_NX2vmBaM:1oYfduIDgYM:V_sGLiPBpWU"img src="http://feeds.feedburner.com/~ff/reuters/scienceNews?i=oB_NX2vmBaM:1oYfduIDgYM:V_sGLiPBpWU" border="0"/img/a
/divimg src="http://feeds.feedburner.com/~r/reuters/scienceNews/~4/oB_NX2vmBaM" height="1" width="1" alt=""/